Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2005;31(3):239–244. doi: 10.1385/MB:31:3:239

Tumor necrosis factor as a pharmacological target

Pietro Ghezzi 1,2,✉, Anthony Cerami 2
PMCID: PMC7101943  PMID: 16230774

Abstract

As indicated by its name, tumor necrosis factor (TNF), cloned in 1985, was originally described as a macrophage-derived endogenous mediator that can induce hemorrhagic necrosis of solid tumors and kill some tumor cell lines in vitro. Unfortunately, its promising use as an anticancer agent was biased by its toxicity, which was clear soon from the first clinical trials with TNF in cancer. Almost at the same time TNF was being developed as an anticancer drug, it became clear that TNF was identical to a mediator responsible for cachexia associated with sepsis, which was termed cachectin. This research led to the finding that TNF is, in fact, the main lethal mediator of sepsis and to the publication of a huge number of articles showing that TNF inhibits the toxic effects of bacterial endotoxins, which are now described as systemic inflammatory response. Although the clinical trials with anti-TNF in sepsis have not been successful thus far, undoubtedly as a result of the complexity of this clinical setting, these studies ultimately led to the identification of TNF as a key inflammatory mediator and to the development of anti-TNF molecules (soluble receptors and antibodies) for important diseases including rheumatoid arthritis and Crohn’s disease. On the other side, the mechanisms by which TNF and related molecules induce cell death have been studied in depth, and their knowledge might, in the future, suggest means of improve the therapeutic index of TNF in cancer.

Index Entries: Tumor necrosis factor, cachectin, sepsis, inflammation

References

  • 1.Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229:869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  • 2.Tracey K. J., Fong Y., Hesse D. G., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  • 3.American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 1992;20:864–874. doi: 10.1097/00003246-199206000-00025. [DOI] [PubMed] [Google Scholar]
  • 4.Dayer J. M., Beutler B., Cerami A. Cachectin/tumor necrosis factor stimulates collage-nase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 1985;162:2163–2168. doi: 10.1084/jem.162.6.2163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986;322:547–549. doi: 10.1038/322547a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Seckinger P., Isaaz S., Dayer J. M. A human inhibitor of tumor necrosis factor alpha. J. Exp. Med. 1988;167:1511–1516. doi: 10.1084/jem.167.4.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Seckinger P., Zhang J. H., Hauptmann B., Dayer J. M. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc. Natl. Acad. Sci. USA. 1990;87:5188–5192. doi: 10.1073/pnas.87.13.5188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J. Biol. Chem. 1990;265:1531–1536. [PubMed] [Google Scholar]
  • 9.Beutler B., Krochin N., Milsark I. W., Luedke C., Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science. 1986;232:977–980. doi: 10.1126/science.3754653. [DOI] [PubMed] [Google Scholar]
  • 10.Busso N., Collart M., Vassalli J. D., Belin D. Antagonist effect of RU 486 on transcription of glucocorticoid-regulated genes. Exp. Cell Res. 1987;173:425–430. doi: 10.1016/0014-4827(87)90282-5. [DOI] [PubMed] [Google Scholar]
  • 11.Di Santo E., Sironi M., Mennini T., et al. A glucocorticoid receptor-independent mechanism for neurosteroid inhibition of tumor necrosis factor production. Eur. J. Pharmacol. 1996;299:179–186. doi: 10.1016/0014-2999(95)00840-3. [DOI] [PubMed] [Google Scholar]
  • 12.Swingle W. W., Remington J. W. Role of adrenal cortex in physiological processes. Physiol. Rev. 1944;24:89–127. [Google Scholar]
  • 13.Abernathy R. S., Halberg F., Spink W. W. Studies on mechanism of chloropromazine protection against Brucella endotoxin. J. Lab. Clin. Med. 1957;49:708–715. [PubMed] [Google Scholar]
  • 14.Lazar G., Agarwal M. K. The influence of a novel glucocorticoid antagonist on endotoxin lethality in mice strains. Biochem. Med. Metab. Biol. 1986;36:70–74. doi: 10.1016/0885-4505(86)90108-8. [DOI] [PubMed] [Google Scholar]
  • 15.Lazar G. J., Duda E., Lazar G. Effect of RU 38486 on TNF production and toxicity. FEBS Lett. 1992;308:137–140. doi: 10.1016/0014-5793(92)81261-J. [DOI] [PubMed] [Google Scholar]
  • 16.Perlstein R. S., Whitnall M. H., Abrams J. S., Mougey E. H., Neta R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology. 1993;132:946–952. doi: 10.1210/en.132.3.946. [DOI] [PubMed] [Google Scholar]
  • 17.Kunkel S. L., Spengler M., May M. A., Spengler R., Larrick J., Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 1988;263:5380–5384. [PubMed] [Google Scholar]
  • 18.Spinas G. A., Bloeash D., Keller U., Zimmerli W., Cammisuli S. Pretreatment with ibuprofen augments circulating tumor necrosis factor-a, interleukin-6, and elastase during acute endotoxemia. J. Infect. Dis. 1991;163:89–95. doi: 10.1093/infdis/163.1.89. [DOI] [PubMed] [Google Scholar]
  • 19.Martich G. D., Danner R. L., Ceska M., Suffredini A. F. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J. Exp. Med. 1991;173:1021–1024. doi: 10.1084/jem.173.4.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Gérard C., Bruyns C., Marchant A., et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 1993;177:547–550. doi: 10.1084/jem.177.2.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.de Waal-Malefyt R., Abrams J., Bennet B., Figdor C., de Vries J. E. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 1991;174:1209–1220. doi: 10.1084/jem.174.5.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Gautam S., Tebo J. M., Hamilton T. A. IL-4 suppresses cytokine gene expression induced by IFN-gamma and/or IL-2 in murine peritoneal macrophages. J. Immunol. 1992;148:1725–1730. [PubMed] [Google Scholar]
  • 23.de Waal Malefyt R., Figdor C. G., Huijbens R., et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J. Immunol. 1993;151:6370–6381. [PubMed] [Google Scholar]
  • 24.Dumoutier L., Renauld J. C. Viral and cellular interleukin-10 (IL-10)-related cytokines: from structures to functions. Eur. Cytokine Netw. 2002;13:5–15. [PubMed] [Google Scholar]
  • 25.Borovikova L. V., Ivanova S., Zhang M., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458–462. doi: 10.1038/35013070. [DOI] [PubMed] [Google Scholar]
  • 26.Tracey K. J. The inflammatory reflex. Nature. 2002;420:853–859. doi: 10.1038/nature01321. [DOI] [PubMed] [Google Scholar]
  • 27.Staal F. J., Roederer M., Herzenberg L. A. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 1990;87:9943–9947. doi: 10.1073/pnas.87.24.9943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Auphan N., DiDonato J. A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286–290. doi: 10.1126/science.270.5234.286. [DOI] [PubMed] [Google Scholar]
  • 29.Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956–959. doi: 10.1126/science.8052854. [DOI] [PubMed] [Google Scholar]
  • 30.Moss M. L., White J. M., Lambert M. H., Andrews R. C. TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today. 2001;6:417–426. doi: 10.1016/S1359-6446(01)01738-X. [DOI] [PubMed] [Google Scholar]
  • 31.Sampaio E. P., Sarno E. N., Galilly R., Cohn Z. A., Kaplan G. Thalidomide selectively inhibts tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 1991;173:699–703. doi: 10.1084/jem.173.3.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Moreira A. L., Sampaio E. P., Zmuidzinas A., Frindt P., Smith K. A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 1993;177:1675–1680. doi: 10.1084/jem.177.6.1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lee J. C., Laydon J. T., McDonnell P. C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739–746. doi: 10.1038/372739a0. [DOI] [PubMed] [Google Scholar]
  • 34.Bianchi M., Bloom O., Raabe T., et al. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J. Exp. Med. 1996;183:927–936. doi: 10.1084/jem.183.3.927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Cohen P. S., Schmidtmayerova H., Dennis J., et al. The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol. Med. 1997;3:339–346. [PMC free article] [PubMed] [Google Scholar]
  • 36.Hommes D., van den Blink B., Plasse T., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. Gastroenterology. 2002;122:7–14. doi: 10.1053/gast.2002.30770. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Biotechnology are provided here courtesy of Nature Publishing Group

RESOURCES